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Background: Biorepositories linked to de-identified electronic medical records
(EMRs) have the potential to complement traditional epidemiologic studies in
genotype-phenotype studies of complex human diseases and traits. A major challenge
in meeting this potential is the use of EMR-derived data to extract phenotypes and
covariates for genetic association studies. Unlike traditional epidemiologic data,
EMR-derived data are collected for clinical care and are therefore highly variable across
patients. The variability of clinical data coupled with the challenges associated with
searching unstructured clinical notes requires the development of algorithms to
extract phenotypes for analysis. Given the number of possible algorithms that could
be developed for any one EMR-derived phenotype, we explored here the impact
algorithm decision logic has on genetic association study results for a single
quantitative trait, high density lipoprotein cholesterol (HDL-C).
Results: We used five different algorithms to extract HDL-C from African American
subjects genotyped on the Illumina Metabochip (n = 11,519) as part of Epidemiologic
Architecture for Genes Linked to Environment (EAGLE). Tests of association between
HDL-C and genetic risk scores for HDL-C associated variants suggest that the genetic
effect size does not vary substantially across the five HDL-C definitions.
Conclusions: These data collectively suggest that, at least for this quantitative trait,
algorithm decision logic and phenotyping details do not appreciably impact genetic
association study test statistics.
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PAGE I studyBackground
Biorepositories linked to de-identified electronic medical records (EMR) are an
emerging resource for genetic association studies [1]. Compared with traditional
epidemiologic studies, EMR-based studies offer multiple advantages including relative
ease of ascertainment, rapid accrual of samples and associated data, longitudinal
measures, and the potential for lengthy follow-up. Another major advantage of
EMR-based or clinic-based studies is their potential for pharmaocogenomics and
other applications associated with personalized medicine.© 2015 Dumitrescu et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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offer multiple challenges when accessed for research such as genetic association
studies. A major challenge of the EMR is that the data are not collected for
research purposes; that is, the data are collected as part of routine clinical care.
Therefore, unlike traditional epidemiologic studies, there is no “baseline” measurement
or examination of all study participants, and the number of overall measurements
and exams can vary widely by patient. This variability is in stark contrast to longitudinal
epidemiologic studies where participants are surveyed and examined uniformly
every few years.
Because of the variable and somewhat erratic nature of the EMR data, investigators
accessing these data for genetic association studies must make specific decisions in de-
veloping phenotype algorithms designed to extract outcomes and covariates for ana-
lysis. For example, for a commonly studied measurement such as body mass index, the
investigator has multiple options including the first height and weight mentioned, the
last height and weight mentioned, an average of all heights and weights mentioned for
all clinic visits, the height and weight mentioned closest to another clinical diagnosis
(such as type 2 diabetes), and so on.
Many of the challenges associated with EMR-based phenotyping are being
addressed by collaborative consortiums such as the electronic MEdical Records and
GEnomics (eMERGE) network, a cooperative group of several DNA biorepositories
in the United States linked to EMRs funded by the National Human Genome
Research Institute [2,3]. A major goal of the eMERGE network is the development
of portable algorithms designed to define disease outcomes for use in genetic
association studies [4]. Algorithms developed under eMERGE have been used
successfully for single study site [5,6] and well as eMERGE-wide studies [7-13], the
latter of which demonstrate the portability of these algorithms despite possible
variations in clinical practice. A portion of the eMERGE EMR-derived phenotypes
have also been mapped back to PhenX variables using the PhenX Toolkit [14],
suggesting that EMR-derived phenotypes are comparable to epidemiologic collected
phenotypes [15].
The eMERGE network has been successful in designing and implementing EMR-
based algorithms for multiple phenotypes; however, it is unclear if the decision
logic underlying each algorithm for phenotypes with repeated measures impacts
downstream analyses for genetic association studies. To explore this possible
impact, we as the Epidemiologic Architecture for Genes Linked to Environment
(EAGLE) as part of the larger Population Architecture using Genomics and
Epidemiology (PAGE) I study [16] conducted a genetic association study for the
commonly measured and studied high density lipoprotein cholesterol (HDL-C). We
created five HDL-C algorithms to extract this quantitative trait from African
American subjects genotyped with the Illumina Metabochip [17] and available in
BioVU, the Vanderbilt biorepository linked to de-identified electronic medical
records [18]. Overall, we demonstrate that the genetic effect size estimates and
levels of significance are similar across all HDL-C extraction methods attempted
suggesting that commonly used decision logic for repeated measures in the EMR
may not have appreciable impacts on downstream analyses conducted for genetic
association studies.
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Study population
All study subjects are drawn from BioVU, Vanderbilt University Medical Center’s
biorespository linked to de-identified electronic medical records. A description of
BioVU, including its oversight and ethics, has been previously published [18,19]. In
brief, DNA is extracted from discarded blood samples drawn for routine clinical
care from Vanderbilt University affiliated outpatient clinics. The DNA sample is
linked to the patient’s de-identified EMR known as the Synthetic Derivative (SD).
The SD contains billing (ICD-9) codes, procedure codes and labs. Prescription
medication, including dose, is available in the SD through MedEx [20], an algorithm that
extracts medications and their signature mentions from free-text entries available in the
EMR. The SD also contains all clinical notes.
As EAGLE, a study site of PAGE I, we genotyped mostly non-European descent DNA
samples available in BioVU as of 2011 on the Illumina Metabochip (described below),
hereto referred as “EAGLE BioVU” (n = 15,863) [21]. The present study is limited
to African Americans within EAGLE BioVU (n = 11,519).HDL-C definitions
HDL-C measurements were extracted from a de-identified EMR using five different
methods. First, for each subject, the median HDL-C value of all documented HDL-C
measurements was collected (“All HDL-C”). Next, both first and last reported HDL-C
were mined from the subject’s laboratory data (“First HDL-C” and “Last HDL-C”).
Lastly, HDL-C values were extracted for subjects both prior to (“pre-medication
HDL-C”) or following (“post-medication HDL-C”) evidence of lipid-lowering medications
and the median value was reported. EAGLE BioVU clinical notes were searched for
evidence of lipid-lowering drugs for each subject using medication class as well as
medication generic and brand names (Table 1). For each mention of lipid-lowering
drug use, we extracted the date of medication mention to compare against date of
HDL-C lab to determine if that measurement of HDL-C was “pre-medication” orTable 1 Lipid-lowering medication class and list of drugs
Fibrates Resisns Statins






Colestipol (Colestid®) Fluvastatin (Lescol®)




Lovastatin + niacin (Advicor®)
Atorovastatin + amlodipine (Caduet®)
Simvastatin + ezetimibe (Vytorin™)
Four major medication classes containing lipid-lowering medications were used to search the clinical notes: fibrates,
niacin, resins, selective cholesterol absorption inhibitors (Ezetimibe or Zetia®), and statins (also known an HMG CoA
reductase inhibitors). For each of the medication classes included in the search, we have listed the specific drugs
considered, including both the generic and brand names.
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were considered “pre-medication HDL-C.” All HDL-C values used in this analysis were
collected when the subject was 18 years or older.Genotyping and SNP selection
A total of 15,863 DNA samples from mostly non-European descent subjects were genotyped
on the Illumina Metabochip, including 11,519 African Americans, by Vanderbilt University
Center for Human Genetics Research DNA Resources Core. The Illumina Metabochip is a
custom array of approximately 200,000 variants chosen as GWAS-identified index variants
or GWAS-identified regions for fine-mapping based on data from the first iteration of the
1000 Genomes Project [17]. Quality control of the Illumina Metabochip data for EAGLE
BioVU followed the quality control procedures outlined in Buyske et al. [22].
Based on a previous fine-mapping study of HDL-C using Metabochip [23], seven of
the 22 fine-mapped HDL-C loci exhibited evidence of association at p < 1x10−4 in African
Americans. The seven index SNPs from these seven associated HDL-C loci were selected
for use in calculating the genetic risk score (GRS, Table 2).Statistical methods
Both a weighted and unweighted GRS were calculated in PLINK [24]. In general, the
GRS is calculated for each subject by counting the number of effect alleles (0, 1, or 2)
across each SNP, multiplying that number by the known effect size (for the unweighted
GRS, effect sizes were set equal to one), summing those values, and dividing by the
number of non-missing SNPs, thus providing the average score per SNP. Effect estimates
for the weighted GRS were based on the meta-analysis of PAGE African Americans [23].
Linear regression, adjusted for sex, with GRS as the independent variable and HDL-C
measurement as the dependent variable was used to determine the beta coefficient.Results
Approximately 43% of the 11,519 African American subjects genotyped on the Illumina
Metabochip as part of EAGLE had at least one HDL-C measurement available in the
EMR (Table 3). The median number of clinic visits and medical records lengths in
years was three each while the median ICD-9 code mentions (for unique codes) was
54. The median value for HDL-C ranged from 48–51 across the five different HDL-C
definitions explored here (Table 3).Table 2 SNPs used to calculate the genetic risk score for HDL-C in African Americans
SNP Gene of interest Effect Allele Effect on HDL-C† (mg/dl)
rs247617 CETP C −0.111
rs1077834 LIPC A −0.033
rs10096633 LPL G −0.042
rs189069311 APOA5 A −0.080
rs255054 LCAT A −0.042
rs6601299 PPP1R3B A −0.063
rs4810479 PLTP G −0.029
†Beta coefficients were drawn from meta-analysis results of PAGE African Americans [23].
Table 3 EAGLE BioVU African American demographics for HDL-C
Variable No. Obs. Median IQR
Medical record length (years) 4,912 3 8
Clinic visits (N) 4,912 3 6
ICD-9 codes (N)† 4,897 54 85
All HDL-C (mg/dl) 4,890 51 23
First HDL-C (mg/dl) 4,912 50 23
Last HDL-C (mg/dl) 4,912 49 22
pre-medication HDL-C (mg/dl) 4,074 51 23
post-medication HDL-C (mg/dl) 2,086 48 22
Number of observations (No. Obs.) as well as medians and interquartile ranges (IQR) are given for each variable. †Includes
only unique ICD-9 codes per individual.
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(Table 2) for each African American in EAGLE BioVU with at least one HDL-C
measurement. The number of HDL-C risk alleles ranged from 3 to 12, which the
majority of subjects having 8 risk alleles (Figure 1).
We then performed tests of association for each of the five HDL-C definitions using the
unweighted GRS as the independent variable. The unweighted GRS was significantly
associated with each of the five HDL-C definitions, and the levels of significance ranged
from 4.06 × 10−86 (post-medication HDL-C; n = 2,085) to 3.73 × 10−197 (first HDL-C;
n = 4,910). Because level of significance is influenced by sample size, we then
plotted each resulting beta and 95% confidence intervals to compare the effect
sizes of the unweighted GRS across the five different HDL-C definitions (Figure 2).
The unweighted GRS effect size was similar across the five different HDL-C definitions
(Figure 2). Results from the weighted GRS do not appreciably differ from the unweighted
results (data not shown).Discussion
We demonstrate here that for HDL-C, a commonly studied quantitative trait for
cardiovascular disease risk, algorithm decision logic and phenotyping details applied
to repeated measures available in the EMR do not appreciably affect downstreamFigure 1 Distribution of HDL-C risk alleles in EAGLE BioVU African Americans.
Figure 2 Additive effects of HDL-C risk alleles on various HDL-C measurements. Effect sizes (betas) from the
linear regression analysis with the unweighted GRS, adjusted for sex, are shown as expected HDL-C levels
(in mg/dl; black diamonds), along with their 95% confidence intervals.
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with on-going algorithm development within the eMERGE network [5,25], suggest
that phenotypes derived from EMR-based repositories are robust to the underlying
variability inherent in clinical collections. Although not explicitly tested here, the
similarities of genetic effect sizes observed here for the five HDL-C definitions in
the same sample suggest that any one of these EMR-derived test statistics robust to
algorithm decision logic can be included in meta-analyses with traditional epidemiologic
studies.
While our data suggest that EMR-derived phenotypes may be robust to certain aspects
of the algorithm decision logic and phenotyping details, these data do not imply that
genetic association studies are not impacted by poor phenotyping. Substantial literature
has documented the need for rigorous case/control phenotyping as misclassification of
either can lead to loss of power [26,27]. Careful phenotyping can also lead to insights into
biological mechanisms or disease processes [28,29]. Finally, careful phenotyping is also
essential for creative study design and genetic discovery [30].
The present study focuses on examining the impact algorithm decision logic has on
genetic associations related to a single quantitative trait, HDL-C. As such, the conclusions
offered here may be limited to HDL-C or to quantitative traits defined from repeated
measures available in the EMR. Further study is needed to more fully explore the
limitations and impact algorithm decision logic may have on genetic association
studies for binary clinical outcomes such as myocardial infarction or pharmacogenomic
studies for traits such as warfarin dosing. For the HDL-C data included here, additional
limitations of the present study include limitations associated with extracting HDL-C
from the EMR. For example, we searched clinic notes for mentions of lipid-lowering
medication classes and drugs (genetic and brand names), but we did not include
any common misspellings of these search terms. It is possible, therefore, that the
“pre-medication” HDL-C definition contains HDL-C measurements while the subject was
on lipid-lowering medication. Another limitation of the EMR is that, unlike most
epidemiologic studies, fasting status or time to last meal is not available as a structured
field. Here, we assumed that the HDL-C measured in EAGLE BioVU was measured for
subjects who fasted for at least eight hours. This assumption is most likely incorrect, but
its violation is unlikely to impact HDL-C levels substantially.
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present here tests of association between various HDL-C derived variables and an
unweighted GRS. The unweighted GRS, by design, is calculated by the number of risk
alleles at loci known to be significantly associated with HDL-C levels. Therefore, with
only a few thousand samples, we were able to statistically replicate the expected
association between the unweighted GRS and the various HDL-C variables to further
examine the genetic effect sizes estimated from these tests of associations. While the
sample size of the present study was large enough for replicating known associations
such as the loci represented in the unweighted GRS, the sample size is not large
enough to perform discovery studies with the entire Metabochip dataset, even when
limited to common variation (minor allele frequency >5%). Indeed, tests of association
between the various HDL-C variables and common variants on the Metabochip
failed to identify a statistically significant association after correction for multiple
testing (data not shown). Furthermore, neither significance rankings nor genetic
effect sizes could be reliably compared across HDL-C variables given the chance
findings of non-significant tests of associations. Larger sample sizes are needed to
make comprehensive comparisons of genetic effect sizes and significance rankings
for EMR-derived phenotypes susceptible to algorithm decision logic and pheno-
typing details.
Despite the limitations, this study had multiple strengths including the depth of
the clinical data and the diversity of EAGLE BioVU. EMR-derived datasets such as
EAGLE BioVU coupled with genotype and sequence data promise to enrich existing and
complimentary datasets for future genetic association studies for complex human diseases
and traits.Conclusions
These data collectively suggest that, at least for HDL-C, algorithm decision logic and
phenotyping details do not appreciably impact genetics association study tests statistics.
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